Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor.
The present study utilizes an in vivo murine tumor expressing human Her-2/neu to evaluate potential Her-2/neu vaccines consisting of either full length or various subunits of Her-2/neu delivered in either protein or plasmid DNA form. Our results demonstrate that protective immunity against Her-2/neu-expressing tumor challenge can be achieved by vaccination with plasmid DNA encoding either full length or subunits of Her-2/neu. Partial protective immunity was also observed following vaccination with the intracellular domain (ICD), but not extracellular domain (ECD), protein subunit of Her-2/neu. The mechanism of protection elicited by plasmid DNA vaccination appeared to be exclusively CD4 dependent, whereas the protection observed with ICD protein vaccination required both CD4 and CD8 T cells.
Foy
T M
TM
Corixa Corporation, Seattle, WA 98104, USA. info@corixa.com
Bannink
J
J
Sutherland
R A
RA
McNeill
P D
PD
Moulton
G G
GG
Smith
J
J
Cheever
M A
MA
Grabstein
K
K
D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000235:genetics / Q000494:pharmacology*; D005260:Female; D018734:Genes, erbB-2; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D021122:Protein Subunits; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D013945:Thymoma / Q000276:immunology / Q000473:pathology / Q000628:therapy; D013953:Thymus Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy; D014407:Tumor Cells, Cultured; D019444:Vaccines, DNA / Q000235:genetics / Q000494:pharmacology*
D019496:Cancer Vaccines; D021122:Protein Subunits; D018719:Erb-b2 Receptor Tyrosine Kinases; D019444:Vaccines, DNA